Table 3 Proportion of resistance to pyrazinamide and second-line anti-TB drugs among patients with MDR-TB, Djibouti nationwide drug-resistance survey, 2014–2015.

From: Culture and Next-generation sequencing-based drug susceptibility testing unveil high levels of drug-resistant-TB in Djibouti: results from the first national survey

 

New cases (n = 14)

Previously treated cases (n = 20)

Total (n = 34)

Drug

Resistance profile

n

% (CI95%)

n

% (CI95%)

n

% (CI95%)

PZA

R

10

71.43 (45.4; 88.3)

13

65.0 (43.3; 81.9)

23

67.7 (50.8–80.9)

AMK/KAN

R

2

14.3 (4.0; 39.9)

4

20.0 (8.1; 41.6)

6

17.7 (8.4; 33.5)

CAPREO

R

3

21.4 (7.6; 47.6)

7

35.0 (18.1; 56.7)

10

29.4 (16.8; 46.2)

FQs

R

0

0 (0.0; 21.5)

0

0 (0.0; 16.1)

0

0 (0.0; 10.2)

  1. PZA: pyrazinamide; AMK: amikacin; KAN: kanamycin; CAPREO: capreomycin; FQs: fluoroquinolones; R: resistant.
Back to article page